Key Points Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well. The biotech could match Wall Street's price target over the next 12 months. 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ: AXSM) has been a great stock to own over the past five years. The company's shares have climbed by about 660%. However, Wall Street remains excited about the company's prospects. Axsome Therapeutics' average price target (according to Yahoo! Finance) is $285.42, implying a 35% upside from its current level. Could the stock really gain that much over the next 12 months? Image source: The Motley Fool. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.